Nascent Biotech, Inc. (NBIO)

Nascent Biotech Income Statement

Financials in millions USD. Fiscal year is April - March.

Year Ending	TTM	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Revenue	0	0	0	1	0.75	0
Revenue Growth (YoY)	-	-	-	33.33%	-	-
Cost of Revenue	0	0	0	0	0	0
Gross Profit	-0	0	0	1	0.75	0
Selling, General & Admin	1.89	2.03	1.49	0.93	1.83	3.15
Research & Development	0.14	0.2	0.27	0.2	0.32	0.29
Other Operating Expenses	0	1.72	1.5	0.33	-0	0
Operating Expenses	2.23	2.23	2.14	1.46	2.15	3.45
Operating Income	-2.23	-2.23	-2.16	-0.46	-1.4	-3.45
Interest Income	0.01	0.01	0	0	0	0
Interest Expense	0.41	-0.39	1.72	0.34	0.34	0.09
Other Expense / Income	-0.91	0.25	-3.29	-0.32	-0.78	0.47
Pretax Income	-2.09	-2.09	-2.8	-0.47	-0.96	-4
Income Tax	0.36	0	2.21	-0.32	0.36	0.09
Net Income	-2.09	-2.09	-2.8	-0.15	-1.31	-4.09
Shares Outstanding (Basic)	171	156	119	108	72	34
Shares Outstanding (Diluted)	171	156	119	108	72	34
Shares Change	29.47%	31.35%	10.05%	48.93%	110.34%	14.30%
EPS (Basic)	-0.01	-0.01	-0.02	-0.00	-0.02	-0.12
EPS (Diluted)	-0.01	-0.01	-0.02	-0.00	-0.02	-0.12
Free Cash Flow	-1.19	-1.19	-1.79	0.41	-0.99	-0.55
Free Cash Flow Per Share	-0.01	-0.01	-0.02	0.00	-0.01	-0.02
Gross Margin	-	-	-	100.00%	100.00%	-
Operating Margin	-	-	-	-45.71%	-186.72%	-
Profit Margin	-	-	-	-14.77%	-175.31%	-
Free Cash Flow Margin	-	-	-	41.35%	-131.57%	-
EBITDA	-2.23	-2.23	-2.16	-0.61	-1.42	-3.45
EBITDA Margin	-	-	-	-60.82%	-189.35%	-
Depreciation & Amortization	0.23	0.38	1.34	0	0	0
EBIT	-2.46	-2.61	-3.5	-	-	-

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.